Scholarlink

Background <p>Acute hepatitis B (AHB) and acute hepatitis C (AHC) remain major global health challenges despite the World Health Assembly’s 2030 elimination goals. In addition, the COVID-19 pandemic has disrupted hepatitis control efforts, and sex-specific differences in disease burden remain underexplored. This study aimed to systematically quantify the temporal, geographic, age-, and sex-specific burden of AHB and AHC, as well as the contribution of drug use to disease burden at the global, regional, and national levels.</p> Methods <p>Using data from the Global Burden of Disease Study 2021, we analyzed prevalence, mortality, and disability-adjusted life years (DALYs) for AHB and AHC across 204 countries and 21 regions from 1990 to 2021, with a focus on age, sex, and drug-use-related risk factors.</p> Results <p>In 2021, global AHB and AHC cases reached 7.3 million and 0.8 million, representing respective declines of 40.2% and 10.7% since 1990. Despite overall reductions, significant regional and sex disparities persist. Males exhibited consistently higher burdens, influenced by biological and behavioral factors. The proportion of DALYs attributable to drug use increased for both infections, especially for AHC. Unexpectedly, South Asia showed rising AHB-related DALYs despite socioeconomic improvement.</p> Conclusions <p>Although the global burden of AHB and AHC has declined, persistent disparities highlight the need for tailored, virus-specific strategies. Expanding vaccination, screening, antiviral access, and harm-reduction programs is crucial to achieving viral hepatitis elimination by 2030.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sex-specific burdens of acute hepatitis B and C and their attributable risk factors in 204 countries and territories, 1990–2021

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Zhonghua Sun,
  • Yameng Xu,
  • Jiansheng Xiao,
  • Xiaozhu Liu,
  • Yuwen Shangguan,
  • Wencai Wang,
  • Silei Chen,
  • Wenhong Zhang

摘要

Background

Acute hepatitis B (AHB) and acute hepatitis C (AHC) remain major global health challenges despite the World Health Assembly’s 2030 elimination goals. In addition, the COVID-19 pandemic has disrupted hepatitis control efforts, and sex-specific differences in disease burden remain underexplored. This study aimed to systematically quantify the temporal, geographic, age-, and sex-specific burden of AHB and AHC, as well as the contribution of drug use to disease burden at the global, regional, and national levels.

Methods

Using data from the Global Burden of Disease Study 2021, we analyzed prevalence, mortality, and disability-adjusted life years (DALYs) for AHB and AHC across 204 countries and 21 regions from 1990 to 2021, with a focus on age, sex, and drug-use-related risk factors.

Results

In 2021, global AHB and AHC cases reached 7.3 million and 0.8 million, representing respective declines of 40.2% and 10.7% since 1990. Despite overall reductions, significant regional and sex disparities persist. Males exhibited consistently higher burdens, influenced by biological and behavioral factors. The proportion of DALYs attributable to drug use increased for both infections, especially for AHC. Unexpectedly, South Asia showed rising AHB-related DALYs despite socioeconomic improvement.

Conclusions

Although the global burden of AHB and AHC has declined, persistent disparities highlight the need for tailored, virus-specific strategies. Expanding vaccination, screening, antiviral access, and harm-reduction programs is crucial to achieving viral hepatitis elimination by 2030.